#sémaglutide
My current "compounded semaglutide" update is I continue to slowly lose weight (neat perk) and my drinking continues to be literally 1/10th what it used to be which will probably end up seriously extending my life.
January 24, 2026 at 2:32 PM
Some new info from Breen about the planned GLP-1 trial: they plan to test semaglutide, and the manufacturer is "willing to collaborate with RECOVER-TLC." The study "will be powered for adults but we do expect to have an adolescent component," Breen said.
January 23, 2026 at 5:26 PM
bunny note to inject semaglutide in tummy instead of leg thid time
January 24, 2026 at 1:14 PM
“But like any world-changing technology, semaglutide drugs have their critics. In this case, it’s health influencers leading the charge. They would rather you fast, switch diets, take up exercise or, better still, spend a nominal amount to join their online programmes and courses.”
We’re finally learning the true side-effects of weight-loss drugs — BBC Science Focus Magazine
Millions of people are now using weight-loss drugs, but it seems there are side-effects that come with the slimmer waistlines
apple.news
January 28, 2026 at 8:38 AM
🫀 Ozempic isn’t just about weight loss — and the data may surprise you.
A landmark clinical trial just showed that semaglutide reduced major heart attacks, strokes, and cardiovascular death by ~20% — even in patients WITHOUT diabetes.
DrAlo.net/blog
January 23, 2026 at 1:44 AM
We got
Jardiance, Januvia, Gardasil, tenofovir disoproxil and Emtricitabine.
Abilify, zetia, tivicay, naltrexone and Ergocalciferol.
Theres. Zolpidem, Xiidra, aripiprazole, and semaglutide.
(So on and so forth)
January 21, 2026 at 5:25 PM
True, but Ozempic is one of two major semaglutide manufacturers. Their main competitor is the American company Eli Lilly with drugs Mounjaro and Zepbound. Eli Lilly also makes insulin.
January 18, 2026 at 5:45 AM
The patent on semaglutide is expiring in India, Canada and Brazil - what’s the patent status of semaglutide in Australia in coming months?
January 17, 2026 at 4:46 AM
Semaglutide is Novo-only, but Lilly’s tirzepatide is also a GLP-1 drug (and generally a little more effective than Ozempic.)
January 18, 2026 at 9:24 PM
this is a rare bit of probably-good news from SCOTUS

this case is about what happens when a patented drug goes off-patent, but one or more specific *uses* remain patented

Eg, imagine if "treating diabetes by administering semaglutide" expires, but "semaglutide for weightloss" is still patented
US Supreme Court to hear 'skinny label' patent fight involving Amarin
The U.S. Supreme Court agreed on Friday to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa that could have broad consequences for generic drug makers and so-called "skinny ...
www.reuters.com
January 16, 2026 at 10:17 PM
Pharmac reviewing applications to fund Wegovy or semaglutide, a GLP-1 receptor agonist for weight loss. Reasons to OK Wegovy also apply to gonadotropin-releasing hormone agonist (used as puberty blockers). Both medicines save lives thru hormone responses.
#NZpol
www.rnz.co.nz/news/nationa...
Pharmac seeking clinical advice on funding Wegovy weight loss medication
Pharmac received two applications to fund Wegovy or semaglutide - a GLP-1 receptor agonist for weight loss.
www.rnz.co.nz
January 17, 2026 at 11:04 PM
January 18, 2026 at 6:37 AM
The FDA recently approved the Wegovy pill for obesity.

How does the oral #GLP-1 drug stack up against the #semaglutide injection?

ja.ma/3LDPC1Q
FDA Approves Wegovy Pill for Obesity
This Medical News article discusses the US Food and Drug Administration approval of oral semaglutide, marketed as the Wegovy pill, for the treatment of obesity in adults.
ja.ma
January 16, 2026 at 5:00 PM
Das wird den Orangutan aber nicht beeindrucken, denn:
- die Wohlhabenden werden Insulin bekommen, und wenn die Armen krepieren, hat ihn das bisher auch nicht gejuckt.
- Semaglutide sind als Typ II Antidiabetika nicht essentiell, und als "Abnehmspritze" Luxus.
- Maersk ist durch Korea ersetzbar.
January 18, 2026 at 8:31 AM
New BMJ meta-analysis: Most patients regain lost weight within 2 years of stopping popular obesity drugs like semaglutide and tirzepatide. Benefits fade fast without long-term plans.

www.news-medical.net/news/2026011...
Most patients regain lost weight within two years of stopping obesity drugs
Weight management medications show limited long-term effects, with rapid weight regain post-treatment, emphasizing the need for sustainable obesity strategies.
www.news-medical.net
January 13, 2026 at 2:25 PM
As of today, I've lost 25 lbs in 4 months on semaglutide! 🎉

#GLP1
January 10, 2026 at 11:59 PM
Depending on where you live, if you have medicaid it can help cover semaglutide
January 11, 2026 at 6:19 PM
It's a pity there's nowhere which measures both currency and adults' weight in pounds any more, because I acknowledge that currency-unit-per-lb would be a mildly amusing bit when discussing semaglutide and its variants
January 9, 2026 at 3:40 PM
The big business of Ozempic copycats as semaglutide set to go generic, by Danielle Groen secure.campaigner.com/csb/Public/s... via @theglobeandmail.com
January 8, 2026 at 1:48 PM
So you're telling me that if you stop using semaglutide or similar and don't make any other changes to your diet and lifestyle, you'll put back on the weight you lost?
a cartoon character says i 'm shocked in front of a fence
ALT: a cartoon character says i 'm shocked in front of a fence
media.tenor.com
January 8, 2026 at 1:29 PM
Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease
ABSTRACTBackground. Type 2 diabetes (T2D) is the leading cause of chronic kidney disease (CKD) and kidney failure globally. Semaglutide, a glucagon-like pe
academic.oup.com
January 8, 2026 at 5:30 PM
L’ère de l’exclusivité de Novo Nordisk sur le sémaglutide, la molécule à la base de l’Ozempic, touche à sa fin au Canada. Le brevet qui protège l’ingrédient actif de ce médicament est arrivé à échéance le 4 janvier. ici.radio-canada.ca/rci/fr/nouve...
Expiration du brevet d’Ozempic : la guerre des prix commence | RCI
Le brevet protégeant le sémaglutide, l’ingrédient actif de ce médicament souvent utilisé pour traiter l’obésité, est arrivé à échéance le 4 janvier.
ici.radio-canada.ca
January 8, 2026 at 5:30 PM
New @cam.ac.uk and @ucl.ac.uk research finds people prescribed weight loss drugs such as semaglutide and tirzepatid may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss.

🧵 (1/4)
January 8, 2026 at 10:30 AM
Nordisk casts semaglutide
Doughboy loses 1.35E+11 blubber
Doughboy feels cold
Doughboy feels cold
Doughboy is freezing
Doughboy has died
January 7, 2026 at 12:16 PM